Rise In Cases Of Autoimmune Diseases To Expand Kinase Inhibitors: The Driving Engine Behind Kinase Inhibitors Market Evolution in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Kinase Inhibitors Market Size Growth Forecast: What to Expect by 2025?
The market size for kinase inhibitors has seen robust expansion in the recent past. The value of the market is projected to jump from $62.75 billion in 2024 to $67.21 billion in 2025, marking a compound annual growth rate (CAGR) of 7.1%. Factors influencing growth during the historic period include heightened incidence of cancer, advancements in targeted treatment approaches, increase in healthcare spending, sanction of new kinase inhibitors and a rise in the embrace of personalized medicine.

How Will the Kinase Inhibitors Market Size Evolve and Grow by 2029?
The market for kinase inhibitors is predicted to witness substantial growth in the coming years, expected to expand to a staggering $88.56 billion by 2029, with a compound annual growth rate (CAGR) of 7.1%. This anticipated growth within the timeframe can be credited to ongoing R&D efforts, the arrival of new kinase inhibitors, broadening uses beyond just oncology, heightened investment in the biotech sector, and a rise in awareness of precision medicine. The forecast period is also set to see some major trends, such as the expansion of precision oncology treatments, the creation of combination therapies, a rising emphasis on rare and difficult-to-treat cancers, the evolution of biomarker-guided drug creation, and the increased use of cutting-edge sequencing technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

What Drivers Are Propelling the Growth of Kinase Inhibitors Market Forward?
The rise in autoimmune diseases occurrences is predicted to boost the kinase inhibitors market's growth. Autoimmune diseases are a diverse range of disorders marked by an aberrant immune response where the immune system erroneously harms healthy cells, tissues, and organs. The escalating prevalence of those diseases results from lifestyle and diet alterations, environmental pollution, genetic predisposition, stress, microbial imbalances, and the augmenting cases of chronic ailments like obesity and diabetes. Kinase inhibitors offer therapeutic advantages for autoimmune diseases by regulating the immune system, lessening inflammation, and easing symptoms such as psoriatic and rheumatoid arthritis. For instance, as per the National Psoriasis Foundation in December 2022, Psoriasis affected over 8 million people in America and 125 million people globally, which makes up 2 to 3% of the population. Moreover, as per the Centers for Disease Control and Prevention in September 2022, Diabetes was diagnosed in 28.7 million individuals of all ages, equating to 8.7% of the US population. Out of this, 5.7% of all confirmed diabetes cases in the US, or 1.6 million people aged 20 and above, reported having type 1 diabetes and needed insulin. Hence, the rise in autoimmune disease occurrences is pushing the growth of the kinase inhibitors market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15841&type=smp

What Are the Key Trends Driving Kinase Inhibitors Market Growth?
In the kinase inhibitors market, major businesses are striving to meet the untreated demands of autoimmune and inflammatory diseases treatments by creating selective tyrosine kinase 2 (TYK2) inhibitors. These inhibitors are particularly effective in cancer treatments, as they modulate immune responses and lessen inflammation, enhancing the body's capacity to target and eliminate cancer cells and creating a less conducive environment for tumour growth. For example, Bristol-Myers Squibb Company, a pharmaceutical company based in the United States, gained U.S. Food and Drug Administration (FDA) approval for Sotyktu (deucravacitinib) in September 2022. Sotyktu, a selectively oral tyrosine kinase 2 (TYK2) inhibitor, is designed to treat adults with moderate-to-severe plaque psoriasis in need of systemic therapy or phototherapy. The unveiling of Sotyktu represents a major leap forward in the treatment of plaque psoriasis, providing a fresh alternative for patients who might not efficiently respond to existing therapies.

What Are the Key Segments in the Kinase Inhibitors Market?
The kinase inhibitors market covered in this report is segmented -

1) By Type: Tyrosine Kinase Inhibitors, Multikinase Inhibitors, mTOR Kinase Inhibitors, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Application: Oncology, Inflammatory Diseases
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Tyrosine Kinase Inhibitors: EGFR Inhibitors, HER2 Inhibitors, BCR-ABL Inhibitors, Other Tyrosine Kinase Inhibitors
2) By Multikinase Inhibitors: VEGFR Inhibitors, PDGFR Inhibitors, FGFR Inhibitors, Other Multikinase Inhibitors
3) By MTOR Kinase Inhibitors: Everolimus, Temsirolimus, Other MTOR Kinase Inhibitors
4) By Other Types: JAK Inhibitors, ROCK Inhibitors, CDK Inhibitors, Other Kinase Inhibitors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15841&type=smp

Who Are the Key Players Shaping the Kinase Inhibitors Market's Competitive Landscape?
Major companies operating in the kinase inhibitors market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Dr. Reddy's Laboratories Ltd., Endo International Inc., Amneal Pharmaceuticals LLC, Lupin Limited, Exelixis Inc., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hutchison China MediTech Limited, Akorn Incorporated, Ocular Therapeutix Inc., Sierra Oncology Inc

What Geographic Markets Are Powering Growth in the Kinase Inhibitors Market?
Asia-Pacific was the largest region in the kinase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15841

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.